Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes

FASEB J. 2020 Jul;34(7):8787-8795. doi: 10.1096/fj.202001115R. Epub 2020 Jun 11.

Abstract

The dynamics, such as transmission, spatial epidemiology, and clinical course of Coronavirus Disease-2019 (COVID-19) have emerged as the most intriguing features and remain incompletely understood. The genetic landscape of an individual in particular, and a population in general seems to play a pivotal role in shaping the above COVID-19 dynamics. Considering the implications of host genes in the entry and replication of SARS-CoV-2 and in mounting the host immune response, it appears that multiple genes might be crucially involved in the above processes. Herein, we propose three potentially important genetic gateways to COVID-19 infection; these could explain at least in part the discrepancies of its spread, severity, and mortality. The variations within Angiotensin-converting enzyme 2 (ACE2) gene might constitute the first genetic gateway, influencing the spatial transmission dynamics of COVID-19. The Human Leukocyte Antigen locus, a master regulator of immunity against infection seems to be crucial in influencing susceptibility and severity of COVID-19 and can be the second genetic gateway. The genes regulating Toll-like receptor and complement pathways and subsequently cytokine storm induced exaggerated inflammatory pathways seem to underlie the severity of COVID-19, and such genes might represent the third genetic gateway. Host-pathogen interaction is a complex event and some additional genes might also contribute to the dynamics of COVID-19. Overall, these three genetic gateways proposed here might be the critical host determinants governing the risk, severity, and outcome of COVID-19. Genetic variations within these gateways could be key in influencing geographical discrepancies of COVID-19.

Keywords: ACE; COVID-19; HLA; SARS-CoV-2; cytokine storm; genetics; immunity.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Betacoronavirus / physiology*
  • COVID-19
  • Complement Activation / genetics*
  • Coronavirus Infections / complications
  • Coronavirus Infections / genetics*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / transmission
  • Cytokine Release Syndrome / etiology
  • Cytokine Release Syndrome / genetics
  • Disease Resistance / immunology
  • Genetic Predisposition to Disease
  • Genetic Variation
  • HLA Antigens / genetics*
  • HLA Antigens / immunology
  • Host-Pathogen Interactions / genetics*
  • Host-Pathogen Interactions / immunology
  • Humans
  • Inflammation
  • Metagenomics
  • Mutation, Missense
  • Pandemics*
  • Peptidyl-Dipeptidase A / genetics*
  • Peptidyl-Dipeptidase A / physiology
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / genetics*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / transmission
  • Prognosis
  • Quantitative Trait Loci
  • Racial Groups / genetics
  • Receptors, Virus / genetics*
  • Receptors, Virus / physiology
  • Risk
  • SARS-CoV-2
  • Toll-Like Receptors / genetics*
  • Toll-Like Receptors / immunology
  • Treatment Outcome

Substances

  • HLA Antigens
  • Receptors, Virus
  • Toll-Like Receptors
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2